Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase 3, registration study of MAT2203 for the prevention of invasive fungal infections (IFIs) in patients on immunosuppressive therapy while receiving chemotherapy for hematologic malignancies

Next Previous
Trial Profile

Pivotal phase 3, registration study of MAT2203 for the prevention of invasive fungal infections (IFIs) in patients on immunosuppressive therapy while receiving chemotherapy for hematologic malignancies

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amphotericin B (Primary)
  • Indications Mycoses
  • Focus Registrational; Therapeutic Use
  • Sponsors Matinas BioPharma

Most Recent Events

  • 27 Sep 2023 According to a Matinas BioPharma media release, company announced that MAT2203 oral LNC formulation will be featured in an oral company pipeline presentation at IDWeek, being held October 11-15 at the Boston Convention and Exhibition Center.
  • 15 Mar 2023 According to a Matinas BioPharma media release, company will have a planned meeting with FDA to discuss safety, efficacy, and tolerability of oral MAT2203 and feedback from this meeting will be instrumental in guiding efforts to secure non-dilutive funding from Biomedical Advanced Research and Development Authority (BARDA) and/or the National Institutes of Health (NIH), as well as in advancing ongoing discussions with potential partners for further development of MAT2203.
  • 15 Mar 2023 According to a Matinas BioPharma media release, company to seek guidance from US FDA for this study for treatment of invasive fungal infections.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top